Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy
نویسندگان
چکیده
منابع مشابه
Optimizing Dendritic Cell Preparation for Fusion with Melanoma Cells
Background: Fusion of dendritic cells (DCs) with melanoma cells could reinforce the antigenicity of tumors as a strategy for the treatment of malignant melanoma. However, the insufficient quantity of DCs and the low fusion efficiency limits the development of such approach. Objective: To define the dosage of the stimulating factors as well as the induction condition for the optimal DCs prepara...
متن کاملUpdate on checkpoint blockade therapy for lymphoma
Although cancer cells express antigens recognizable to the immune system, tumors employ a number of diverse mechanisms aimed at subverting the host anti-tumor immune response. Tumor immune evasion pathways have been most thoroughly studied in solid tumors. However, emerging data has demonstrated that malignancies of hematopoietic origin are also able to co-opt their local environment in order t...
متن کاملBone marrow dendritic cells deficient for CD40 and IL-23p19 are tolerogenic in vitro
Objective(s): In addition to pro-inflammatory role, dendritic cells (DCs) can also be anti-inflammatory when they acquire tolerogenic phenotype. In this study we tested the role of CD40 and IL-23p19 in antigen presenting function of bone marrow-derived DCs (BMDCs) by comparing BMDCs derived from CD40 knockout (CD40KO-DCs) and IL-23p19 (IL-23p19KO-DCs) knockout mice wit...
متن کاملImmune Checkpoint Blockade in Cancer Therapy.
Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Food and Drug Administration for the treatment of advanced melanoma, and additional regulatory appr...
متن کاملEvidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
Significant advances in the treatment of melanoma have been made with BRAF-targeted therapy and immune checkpoint blockade, and these strategies are now being combined empirically in clinical trials. Potential synergy is demonstrated in murine models and in analysis of longitudinal biopsies from patients on trial, however important questions remain regarding toxicity, optimal timing and sequenc...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal for ImmunoTherapy of Cancer
سال: 2021
ISSN: 2051-1426
DOI: 10.1136/jitc-2020-000832